Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...129130131132133134135136137138139...401402»
  • ||||||||||  Journal:  Age-related muscle anabolic resistance: inevitable or preventable? (Pubmed Central) -  Mar 13, 2023   
    This narrative review addresses the key factors and contextual elements involved in reduction of the acute muscle protein synthesis response associated with aging and its varied consequences. Practical interventions focused on dietary protein manipulation are proposed to prevent the onset of anabolic resistance and mitigate its progression.
  • ||||||||||  Journal:  The Geriatric Nutritional Risk Index predicts sarcopenia in patients with cirrhosis. (Pubmed Central) -  Mar 13, 2023   
    The optimal cutoff value of the GNRI for predicting sarcopenia was 102.1 (sensitivity/specificity, 0.768/0.630). The GNRI was significantly associated with sarcopenia and physical performance and could be a helpful screening tool for predicting sarcopenia in patients with cirrhosis.
  • ||||||||||  Enrollment open:  High-Intensity Interval Training for Older Adults (clinicaltrials.gov) -  Mar 13, 2023   
    P=N/A,  N=60, Recruiting, 
    The GNRI was significantly associated with sarcopenia and physical performance and could be a helpful screening tool for predicting sarcopenia in patients with cirrhosis. Not yet recruiting --> Recruiting
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Review, Journal:  Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review. (Pubmed Central) -  Mar 11, 2023   
    The addition of brentuximab vedotin (BV) to AVD, especially in a sequential scheme, has demonstrated good efficacy...Other factors of considerable impact on functional status such as sarcopenia and immunosenescence are currently being studied. A fitness-based treatment choice would also be very useful for relapsed or refractory patients, a more frequent and challenging situation than that is found in young cHL patients.
  • ||||||||||  Journal, FDG PET, Metastases:  Prognostic Value of Sarcopenia and Metabolic Parameters of F-FDG-PET/CT in Patients with Advanced Gastroesophageal Cancer. (Pubmed Central) -  Mar 11, 2023   
    The final model demonstrated improved OS and PFS prognostication when combining clinical parameters with imaging-derived sarcopenia measurements but not metabolic tumor parameters. In summary, the combination of clinical parameters and sarcopenia status, but not standard metabolic values from F-FDG-PET/CT, may improve survival prognostication in patients with advanced, metastatic gastroesophageal cancer.
  • ||||||||||  Biomarker, Clinical, Review, Journal:  Mechanisms of skeletal muscle-tendon development and regeneration/healing as potential therapeutic targets. (Pubmed Central) -  Mar 11, 2023   
    Sarcopenia, a disease in which skeletal muscle function declines, and tendinopathy, which involves chronic tendon dysfunction, are particularly troublesome because there have been no significant advances in their treatment. In this review, we will summarize previous reports on the development and regeneration/healing of skeletal muscle and tendon tissues, including a discussion of the molecular and cellular mechanisms involved that may be used as potential therapeutic targets.
  • ||||||||||  Retrospective data, Journal:  Sarcopenia negatively affects postoperative short-term outcomes of patients with non-cirrhosis liver cancer. (Pubmed Central) -  Mar 11, 2023   
    P=N/A
    In this review, we will summarize previous reports on the development and regeneration/healing of skeletal muscle and tendon tissues, including a discussion of the molecular and cellular mechanisms involved that may be used as potential therapeutic targets. Sarcopenia is closely related to poor short-term postoperative outcomes in non-cirrhosis liver cancer patients and the assessment that combines muscle strength and muscle mass can simply and comprehensively identify it.
  • ||||||||||  Review, Journal:  Exploring Oral Function, Protein Intake, and Risk of Sarcopenia: A Scoping Review. (Pubmed Central) -  Mar 9, 2023   
    The findings of this research will increase awareness among clinicians of the amount and nature of evidence pertaining to the relationship between oral health and risk of compromised muscle mass and function, including data showing that loss of teeth is associated with increased risk of sarcopenia in older people. The findings highlight to researchers the gaps in the evidence and where further research and clarification of the relationship between oral health and risk of sarcopenia is warranted.
  • ||||||||||  Review, Journal:  An elusive consensus definition of sarcopenia impedes research and clinical treatment: a narrative review. (Pubmed Central) -  Mar 9, 2023   
    In this narrative review, we describe the evolution of the consensus group' definition of sarcopenia, address the need for more accurate measures of muscle mass and function, and effective, low-cost treatments (i.e., resistance training and diet) for this disease. Consensus on what constitutes sarcopenia is critical to propel research in the field and, importantly, provide what prognostic value a sarcopenia diagnosis provides and how such a patient would be treated.
  • ||||||||||  Adlumiz (anamorelin) / Helsinn, Ono Pharma
    Trial completion:  Effect of a Ghrelin Receptor Agonist on Muscle and Bone (clinicaltrials.gov) -  Mar 9, 2023   
    P1,  N=32, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  Enrollment closed:  GoMob-in: Goal-directed Mobilization of Medical Inpatients (clinicaltrials.gov) -  Mar 7, 2023   
    P=N/A,  N=160, Active, not recruiting, 
    Initiation date: Oct 2022 --> Oct 2023 Recruiting --> Active, not recruiting